Back to search results

Glyburide for Acute Spinal Cord Injury

This study is testing if an oral medication called Glyburide can protect the spinal cord after a recent injury. Researchers want to see if giving Glyburide soon after a spinal cord injury can help prevent further damage. You might be able to join if you are 18 to 80 years old and have had a recent spinal cord injury in your neck or upper back that was not caused by a penetrating wound. The study will look at how many people can be enrolled quickly after their injury and track any side effects from the Glyburide. The current status of this study is unclear, and it plans to enroll 12 participants.

Study design
This study is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 12 participants.
What's involved
You would receive Glyburide for 72 hours, starting within 8 hours of your injury. You would also have regular lab tests and ECGs during your hospital stay, and adverse events would be monitored daily for up to 14 days or until hospital discharge.
Compensation
Not stated in the trial record.
Follow-up
You would be followed for one year after treatment, with follow-up visits on days 28, 42, 84, 182, and 365 after leaving the hospital.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05426681

Spinal Cord Injury Neuroprotection With Glyburide

Recruiting
PHASE1Ages 18–80InterventionalTreatment
Francis Farhadi
~12 participants
Updated 2026-02-13 on ClinicalTrials.gov
What's tested:GlyBURIDE Oral Tablet

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Rate of recruitment of patients with tSCI within the specified time window.
Measured over within 8 hours of tSCI
+1 more outcome measured

Conditions

Acute Spinal Cord Injury

Explore related trials

Spinal Cord Injury

Where it's being run

1 sites across 1 states
Kentucky1

Study leadership

  • Francis Farhadi, MD, PhD · PRINCIPAL_INVESTIGATOR · University of Kentucky

Who to contact

H. Francis Farhadi, MD, PhD
[email protected]
859-323-5661
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

No life threatening injuries resulting from the traumatic accident
No evidence of sepsis
Acute cervical or thoracic SCI with ASIA Impairment Scale Grade A, B, or C od admission.
Non-penetrating SCI at neurologic level from C2 to C8 or T1 to T12

Exclusion

Unconsciousness or other mental impairment that prevents neurological assessment within the first 8 hours
Acute SCI with ASIA Impairment Scale grade D or E
Currently involved in another non-observational SCI research study or receiving another investigational drug
History of hypersensitivity to sulfonylureas, in particular glyburide, or any of its components
Any condition likely to result in the patient's death within the next 12 months
Severe renal disorder from the patient's history (e.g. dialysis) or baseline eGFR of \< 30 mL/min/1.73 m2
Known severe liver disease, or ALT \> 3 times upper limit of normal or bilirubin
Blood glucose \<55 mg/dL at enrollment or immediately prior to administration of DiaBeta, or a clinically significant history of hypoglycemia
Acute ST elevation myocardial infarction, and/or acute decompensated heart failure, and/or QTc \> 520 ms, and/or known history of cardiac arrest (PEA, VT, VF, asystole), and/or admission for an acute coronary syndrome, myocardial infarction, or coronary intervention (percutaneous coronary intervention or coronary artery surgery) within the past 3 months
Known G6PD enzyme deficiency

What this trial measures

  • Rate of recruitment of patients with tSCI within the specified time window.within 8 hours of tSCI

    A measure of feasibility of undertaking a large phase II study among this population of patients where treatment must begin within a short injury-to-drug time window.

  • Number of drug related adverse events.One year post treatment

    A measure of safety of treating patients with traumatic spinal cord injury with Glyburide administered orally.